nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

01.09.2012 | Reproductive Medicine

IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist fixed protocol in women with PCOS: a randomized trial

verfasst von: Bulent Haydardedeoglu, Esra Bulgan Kilicdag, Ayse Huriye Parlakgumus, Hulusi Bulent Zeyneloglu

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Objective

To compare the IVF/ICSI outcomes of the long GnRH agonist and the fixed GnRH antagonist protocol in women with PCOS.

Design

Randomized controlled trial.

Setting

Baskent University Department of Obstetrics and Gynecology.

Patients

Three hundred women with PCOS.

Interventions

IVF/ICSI following the long GnRH agonist down-regulation or the fixed GnRH antagonist protocols.

Main outcome measures

Ongoing pregnancy rates.

Results

Ongoing pregnancy rates were 36.4 % in the OCP + GnRH agonist group and 35.9 % in the OCP + GnRH antagonist group (p > 0.05). Progesterone levels on the day of hCG (0.76 ± 0.71 vs. 0.58 ± 0.50), endometrial thickness on the day of hCG (11.57 ± 2.50 vs. 10.50 ± 2.01), total gonadotropin used (1388.71 ± 482.39 vs. 1253.25 ± 415.81), and duration of COH (9.07 ± 1.96 vs. 8.39 ± 1.75) were significantly lower in the OCP + GnRH antagonist group.

Conclusion

The OCP + long GnRH agonist and the OCP + fixed GnRH antagonist protocols yield similar ongoing pregnancy rates in women with PCOS. Although this study consisting three hundred patients, seems to be large enough in a single center, we were not able to reach to the actual size of power analysis which was approximately 3,000.

Nur mit Berechtigung zugänglich

Franks S (1995) Polycystic ovary syndrome. N Engl J Med 333:853–861PubMedCrossRef

The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2008) Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 89:505–522CrossRef

Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G (2006) Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update 12:651–671PubMedCrossRef

Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM (2006) GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online 13(5):628–638PubMedCrossRef

Al-Inany HG, Abou-Setta AM, Aboulghar M (2007) Gonadotrophin releasing hormone antagonists for assisted conception: a Cochrane Review. Reprod Biomed Online 14:640–649PubMedCrossRef

Humaidan P, Kol S (2011) Copenhagen GnRH Agonist Triggering Workshop Group. GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update 17(4):510–524PubMedCrossRef

Bahceci M, Ulug U, Ben-Shlomo I, Erden HF, Akman MA (2005) Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study. J Reprod Med 50:84–90PubMed

The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19(1):41–47CrossRef

Ferriman D, Gallwey JD (1961) Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21(11):1440–1447PubMedCrossRef

10.

Urman B, Yakin K (2010) New Turkish legislation on assisted reproductive techniques and centres: a step in the right direction? Reprod Biomed Online 21(6):729–731PubMedCrossRef

11.

Kiliçdag EB, Haydardedeoglu B, Cok T, Hacivelioglu SO, Bagis T (2010) Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles. Arch Gynecol Obstet 281(4):747–752PubMedCrossRef

12.

Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Alexopoulou E, Kolibianakis EM (2010) Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Hum Reprod 25(3):683–689PubMedCrossRef

13.

De Diegler D, Fanchin R, de Moustier B, Bulletti C (1998) The hormonal control of endometrium receptivity: estrogen (E2) and progesterone. J Reprod Immunol 39(1–2):149–166CrossRef

14.

Haydardedeoglu B, Bagis T, Simsek E, Cok T, Hacivelioglu SO, Erkanli S (2009) The impact of rescue in vitro fertilization converted from high-response gonadotropin intrauterine insemination cycles in terms of implantation and pregnancy rates as compared with matched controls. Fertil Steril 92(1):137–142PubMedCrossRef

15.

Kurzawa R, Ciepiela P, Baczkowski T, Safranow K, Brelik P (2008) Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non-obese patients. A prospective randomized study. J Assist Reprod Genet 25(8):365–374PubMedCrossRef

16.

Blockeel C, Sterrenburg MD, Broekmans FJ, Eijkemans MJ, Smitz J, Devroey P, Fauser BC (2011) Follicular phase endocrine characteristics during ovarian stimulation and GnRH antagonist cotreatment for IVF: RCT comparing recFSH initiated on cycle day 2 or 5. J Clin Endocrinol Metab 96(4):1122–1128PubMedCrossRef

17.

Meldrum DR, Scott RT Jr, Levy MJ, Alper MM, Noyes N (2009) Oral contraceptive pretreatment in women undergoing controlled ovarian stimulation in ganirelix acetate cycles may, for a subset of patients, be associated with low serum luteinizing hormone levels, reduced ovarian response to gonadotropins and early pregnancy loss. Fertil Steril 91(5):1963–1965PubMedCrossRef

18.

Kolibianakis EM, Papanikolaou EG, Camus M, Tournaye H, Van Steirteghem AC, Devroey P (2006) Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Hum Reprod 21(2):352–357PubMedCrossRef

19.

Griesinger G, Venetis CA, Marx T, Diedrich K, Tarlatzis BC, Kolibianakis EM (2008) Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis. Fertil Steril 90(4):1055–1063PubMedCrossRef

20.

McLernon DJ, Harrild K, Bergh C, Davies MJ, de Neubourg D, Dumoulin JCM et al (2010) Clinical effectiveness of elective single versus double embryo transfer: meta-analysis of data on individual patients in randomised trials. BMJ 341:c6945PubMedCrossRef

Titel: IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist fixed protocol in women with PCOS: a randomized trial
verfasst von: Bulent Haydardedeoglu
Esra Bulgan Kilicdag
Ayse Huriye Parlakgumus
Hulusi Bulent Zeyneloglu
Publikationsdatum: 01.09.2012
Verlag: Springer-Verlag
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 3/2012
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-012-2348-9

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist fixed protocol in women with PCOS: a randomized trial